RCRC
20.1.2020 12:45:11 CET | Business Wire | Press release
Saudi Arabia’s King Salman Bin Abdul Aziz Al Saud has appointed Fahd Abdulmohsan Al-Rasheed as President of the Royal Commission for Riyadh City (RCRC), following his appointment in 2018 as Advisor at the Royal Court.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005223/en/
Al-Rasheed’s career has featured various leadership roles in key Saudi public and private sector organizations. From January 2008 to September 2018, he served as Chief Executive Officer and Board member of Emaar the Economic City, the publicly listed developer of the King Abdullah Economic City (KAEC).
KAEC is not only the first publicly listed greenfield city in the world, but is also considered one of the largest private sector led projects globally. Located on the Red Sea coast of Saudi Arabia and covering 181 square kilometers, it contains advanced urban and environmental sustainability features. During his tenure at KAEC, Al-Rasheed spearheaded the development of King Abdullah Port, the first private port in the region and one of the world’s 100 largest port facilities. Over 120 local and international companies established a corporate or industrial base in KAEC, making it a leading regional center for logistic and industrial services. Concurrently, Al-Rasheed led the development of multiple residential, utility and recreational projects to make the Economic City an attractive, integrated tourism and residential destination.
Previously, Al-Rasheed served as CFO & Deputy Governor at the Saudi Arabian General Investment Authority (SAGIA) and worked at Saudi Aramco, where he led several corporate finance initiatives.
In addition to his new position as RCRC President, Fahd Al-Rasheed will continue his roles as:
- Vice Chairman of the Board of Trustees of the Prince Mohammed bin Salman College of Business and Entrepreneurship – the first of its kind in the Kingdom – which aims to be an incubator and trainer of business entrepreneurs and future leaders across key sectors (governmental, private sector and civil community foundations). MiSK Foundation, Babson International College and Lockheed Martin Corporation are amongst the college’s founders;
- Founder and Chairman of the non-profit Red Sea Foundation, based in Geneva, which promotes trade across the Red Sea region;
- Board Member of the New Cities Foundation (a non-profit foundation based in Geneva);
- Board Member of Emaar Economic City; King Abdullah Port; and the Diplomatic Quarters Authority in Riyadh.
Al-Rasheed was honored as a Young Global Leader by the World Economic Forum in 2011.
He holds a bachelor’s degree in Business Administration from Washington University in St. Louis, USA, and an MBA from Stanford Business School. He graduated from the Advanced Management Program in Real Estate Development at the Harvard Graduate School of Design.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom